Investment Analysts’ Weekly Ratings Updates for Crinetics Pharmaceuticals (CRNX)

A number of firms have modified their ratings and price targets on shares of Crinetics Pharmaceuticals (NASDAQ: CRNX) recently:

• 5/17/2026 – Crinetics Pharmaceuticals was upgraded by Wall Street Zen from “strong sell” to “sell”.
• 5/11/2026 – Crinetics Pharmaceuticals had its price target lowered by Oppenheimer Holdings, Inc. from $87.00 to $84.00. They now have an “outperform” rating on the stock.
• 5/9/2026 – Crinetics Pharmaceuticals was downgraded by Wall Street Zen from “sell” to “strong sell”.
• 5/8/2026 – Crinetics Pharmaceuticals had its price target lowered by Citizens Jmp from $97.00 to $95.00. They now have a “market outperform” rating on the stock.
• 4/28/2026 – Crinetics Pharmaceuticals had its price target raised by Citizens Jmp from $96.00 to $97.00. They now have a “market outperform” rating on the stock.
• 4/20/2026 – Crinetics Pharmaceuticals had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Insider Buying and Selling at Crinetics Pharmaceuticals

In other news, CEO Richard Scott Struthers sold 21,981 shares of Crinetics Pharmaceuticals stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $37.37, for a total transaction of $821,429.97. Following the completion of the sale, the chief executive officer directly owned 404,778 shares in the company, valued at $15,126,553.86. The trade was a 5.15% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Tobin Schilke sold 6,713 shares of Crinetics Pharmaceuticals stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $39.67, for a total value of $266,304.71. Following the sale, the chief financial officer owned 78,121 shares of the company’s stock, valued at approximately $3,099,060.07. This represents a 7.91% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 142,380 shares of company stock worth $5,569,475 over the last quarter. Insiders own 3.80% of the company’s stock.

Crinetics Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases. The company’s proprietary platform leverages insights into hormone receptor signaling to design small-molecule candidates that address conditions driven by dysregulated hormone activity. Crinetics’ research efforts center on targeting somatostatin, vasopressin and other GPCR-mediated pathways with orally bioavailable molecules intended to improve patient convenience and adherence.

The company’s lead product candidate, paltusotine (formerly CRN04777), is a selective, non-peptide somatostatin receptor type 2 agonist being evaluated for the treatment of acromegaly and carcinoid syndrome diarrhea.